This study is currently recruiting participants. (see Contacts and Locations)

Verified June 2014 by Universitätsklinikum Hamburg-Eppendorf

Sponsor:
Universitätsklinikum Hamburg-Eppendorf

Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
medac GmbH

Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA)

Purpose

This is a multicentre, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. observation alone in patients after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholangiocarcinoma</td>
<td>Drug: Gemcitabine</td>
<td></td>
</tr>
<tr>
<td>Gall Bladder Carcinoma</td>
<td>Drug: Cisplatin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other: Observation</td>
<td></td>
</tr>
</tbody>
</table>

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

Resource links provided by NLM:

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer

Drug Information available for: Cisplatin Gemcitabine Gemcitabine hydrochloride

Genetic and Rare Diseases Information Center resources: Biliary Tract Cancer Gall Bladder Cancer

U.S. FDA Resources

Further study details as provided by Universitätsklinikum Hamburg-Eppendorf:
Primary Outcome Measures:
- Disease free survival (DFS) [Time Frame: Disease free survival rate at 24 months (DFSR@24)] [Designated as safety issue: Yes]

Secondary Outcome Measures:
- Disease free survival rate at 24 months (DFSR@24) [Time Frame: 24 months] [Designated as safety issue: Yes]
- Overall survival [Time Frame: 84 months] [Designated as safety issue: Yes]
- Safety and tolerability (assessed by the rate of patients with adverse events according to NCI CTC AE v4.03) [Time Frame: 24 months] [Designated as safety issue: Yes]
- Quality of life [Time Frame: 48 months] [Designated as safety issue: No]
- Function of biliodigestive anastomosis (in terms of surgical revision, requirement for PTCD) [Time Frame: 48 months] [Designated as safety issue: No]
- Rate and severity of biliary tract infections [Time Frame: 48 months] [Designated as safety issue: No]
- Patterns of disease recurrence [Time Frame: 48 months] [Designated as safety issue: No]
- Loco-regional control (assessed by the rate of patients with hepatic or loco-regional recurrence) [Time Frame: 48 months] [Designated as safety issue: No]

Estimated Enrollment: 450
Study Start Date: April 2014
Estimated Study Completion Date: April 2022
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental: gemcitabine plus cisplatin</td>
<td>Drug: Gemcitabine Drug: Cisplatin Other: Observation</td>
</tr>
<tr>
<td>Observation alone</td>
<td>Other: Observation</td>
</tr>
<tr>
<td>Observation alone</td>
<td></td>
</tr>
</tbody>
</table>

Eligibility
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
All enrolled patients will postoperatively be assessed for eligibility for the treatment phase. Additionally patients not previously enrolled into the trial for whatever finding during surgery will be evaluated for eligibility.
- Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection (mixed tumor entities (HCC/CCA) are excluded)
- Macrophotically complete resection (R0/1) within 6 (-16) weeks before scheduled start of chemotherapy
- ECOG 0-1
- Age >18 years
- Adequate hematologic function
- Adequate liver function
- Adequate renal function
- No active uncontrolled infection, except chronic viral hepatitis under antiviral therapy
- No concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to randomization
- Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women <1 year after the onset of menopause (Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded)
Criteria for initial study enrolment

- Written informed consent
- No prior chemotherapy for cholangiocarcinoma
- No previous malignancy within 3 years or concomitant malignancy, except: non-melanomatous skin cancer or adequately treated in situ cervical cancer
- No severe or uncontrolled cardiovascular disease (congestive heart failure NYHA II or IV, unstable angina pectoris, history of myocardial infarction in the last 3 months, significant arrhythmia)
- Absence of psychiatric disorder precluding understanding of information of trial related topics and giving informed consent
- No serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial
- Fertile women (< 1 year after last menstruation) and procreative men willing and able to use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- No pregnancy or lactation

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02170090

Locations

Germany

University Medical Center Aachen  Not yet recruiting
Aachen, Germany
Contact: Tom Luedde, MD  0241 8035609  tluedde@ukaachen.de

Charite Berlin  Recruiting
Berlin, Germany
Contact: Marianne Sinn, MD  030 450 55 3222  marianne.sinn@charite.de

University Medical Center Bonn  Not yet recruiting
Bonn, Germany
Contact: Kalff, Prof  0049 228 287 15327  kalff@uni-bonn.de

University Medical Center Carl Gustav Carus  Not yet recruiting
Dresden, Germany
Contact: Gunnar Folprecht, MD  0351 458 4794  gunnar.folprecht@uniklinikum-dresden.de

University Medical Center Duesseldorf  Not yet recruiting
Duesseldorf, Germany
Contact: W T Knoefel, Prof  0049 211 81 17350  knoefel@uni-duesseldorf.de

University Medical Center Essen  Not yet recruiting
Essen, Germany
Contact: Stefan Kasper, MD  0049 201 723 2039  stefan.kasper@uk-essen.de

University of Frankfurt  Not yet recruiting
Frankfurt, Germany
Contact: Stefan Zeuzem, Prof  zeuzem@em.uni-frankfurt.de

University Medical Center Freiburg  Recruiting
Freiburg, Germany
Contact: Volker Brass, MD  0049761 270 34010  volker.brass@uniklinik-freiburg.de

University Medical Center Hamburg-Eppendorf  Recruiting
Hamburg, Germany, 20246
Contact: Alexander Stein, MD  004940741056882  a.stein@uke.de

University of Hannover  Not yet recruiting
Hannover, Germany
Contact: Arndt Vogel, Prof  vogel.arndt@mh-hannover.de

University of Heidelberg  Not yet recruiting
Heidelberg, Germany
Contact: K H Weiss, MD  Karl-Heinz.Weiss@med.uni-heidelberg.de
University of Saarland
Homburg, Germany
Contact: Frank Lammert, Prof. frank.lammert@uks.eu

University Medical Center Jena
Jena, Germany
Contact: Udo Lindig, MD 0049 3641 9324586 udo.lindig@med.uni-jena.de

University of Leipzig
Leipzig, Germany
Contact: Albrecht Hoffmeister, MD albrecht.hoffmeister@medizin.uni-leipzig.de

University of Magdeburg
Magdeburg, Germany
Contact: Christoph Kahl, MD 0049 391 7915615

Johannes Gutenberg University of Mainz
Mainz, Germany
Contact: Arndt Weinmann, MD arndt.w.lehnmann@unimedizin-mainz.de

University of Mannheim
Mannheim, Germany
Contact: Nadine Schulte, MD nadine.schulte@umm.de

University of Munich Grosshadern
Munich, Germany
Contact: Markus Rentsch mrentsch@med.uni-muenchen.de

University of Regensburg
Regensburg, Germany
Contact: Elisabeth Schnoy, MD elisabeth.schnoy@ukr.de

University Medical Center Tuebingen
Tuebingen, Germany
Contact: Ruben Plentz, MD 07071 2984457 ruben.plentz@med.uni-tuebingen.de

University of Ulm
Ulm, Germany
Contact: Thomas Ettrich, MD thomas.ettrich@uniklinik-ulm.de

University Medical Center Wuerzburg
Wuerzburg, Germany
Contact: Volker Kunzmann, Prof. 0049931 201 31042 kunzmann_v@medizin.uni-wuerzburg.de

Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Deutsche Krebshilfe e.V., Bonn (Germany)
medac GmbH

Investigators
Principal Investigator: Henning Wege Universitätsklinikum Hamburg-Eppendorf

More Information
No publications provided

Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT02170090 History of Changes
Other Study ID Numbers: ACTICCA-T, 2012-005078-70
Study First Received: June 18, 2014
Last Updated: June 20, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Key words provided by Universitätsklinikum Hamburg-Eppendorf:
adjuvant chemotherapy  translational research
cholangiocarcinoma  multidisciplinary
muscle invasive gall bladder carcinoma  AIO, DGAV, DGVs

Additional relevant MeSH terms: